Avidity Biosciences Inc. (RNA)
26.66
1.08 (4.22%)
At close: Apr 14, 2025, 3:06 PM
4.22% (1D)
| Bid | 26.63 |
| Market Cap | 3.21B |
| Revenue (ttm) | 10.9M |
| Net Income (ttm) | -322.3M |
| EPS (ttm) | -2.89 |
| PE Ratio (ttm) | -9.23 |
| Forward PE | -10.01 |
| Analyst | Buy |
| Ask | 26.71 |
| Volume | 474,669 |
| Avg. Volume (20D) | 1,510,563 |
| Open | 26.32 |
| Previous Close | 25.58 |
| Day's Range | 25.66 - 26.76 |
| 52-Week Range | 21.51 - 56.00 |
| Beta | 1.01 |
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to tr...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 391
Stock Exchange NASDAQ
Ticker Symbol RNA
Analyst Forecast
According to 13 analyst ratings, the average rating for RNA stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 147.52% from the latest price.
Stock ForecastsNext Earnings Release
Avidity Biosciences Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+10.24%
Avidity Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
5 months ago
+12.35%
Avidity Biosciences shares are trading higher. Needham reiterated a Buy rating on the stock.
